

LABORATORY TEST REPORT

| | | | |
|--------------------|--------------------------------------|---------------|------------------------|
| Name | : Mrs. SUJATHA G | | |
| Sample ID | : A1840802 | | |
| Age/Gender | : 23 Years 1 Months 14 Days/Female | Reg. No | : 0312502140038 |
| Referred by | : Dr. M LAKSHMI | SPP Code | : SPL-CV-172 |
| Referring Customer | : V CARE MEDICAL DIAGNOSTICS | Collected On | : 14-Feb-2025 01:28 PM |
| Primary Sample | : Whole Blood | Received On | : 14-Feb-2025 04:07 PM |
| Sample Tested In | : Serum | Reported On | : 14-Feb-2025 06:41 PM |
| Client Address | : Kimtee colony ,Gokul Nagar,Tarnaka | Report Status | : Final Report |


CLINICAL BIOCHEMISTRY

| Test Name | Results | Units | Biological Reference Interval |
|-----------|---------|-------|-------------------------------|
|-----------|---------|-------|-------------------------------|

[PDF Attached](#)
Double Marker

| | | | |
|-----------------------------------|-------|--------|---|
| Free -Beta -HCG (Method: CLIA) | 35.74 | ng/mL | < 2 :Non-Pregnant 5.4 - 393.4 : Pregnant |
| PAPP-A (Method: CLIA) | 11.21 | mIU/mL | < 0.1 : Non-Pregnant 0.1-19.5 : Pregnant |

Interpretation:

| DISORDER | SCREEN POSITIVE/HIGH RISK CUT OFF |
|-------------------|-----------------------------------|
| Trisomy 21 (Down) | < 1:250 |
| Trisomy 18/13 | < 1:100 |
| DISORDER | SCREEN NEGATIVE/LOW RISK CUT OFF |
| Trisomy 21 (Down) | > 1:250 |
| Trisomy 18/13 | > 1:100 |

Note: Statistical evaluation has been done using CE marked PRISCA 5 software. · Screening tests are based on statistical analysis of patient demographic and biochemical data. They simply indicate a high or low risk category. Confirmation of screen positives is recommended by Chorionic Villus Sampling (CVS). · The interpretive unit is MoM (Multiples of Median) which takes into account variables such as gestational age (ultrasound), maternal weight, race, insulin dependent Diabetes, multiple gestation, IVF (Date of Birth of Donor, if applicable), smoking & previous history of Down syndrome. Accurate availability of this data for Risk Calculation is critical. · Ideally all pregnant women should be screened for Prenatal disorders irrespective of maternal age. The test is valid between 9-13.6 weeks of gestation, but ideal sampling time is between 10-13 weeks gestation. · First trimester detection rate of Down syndrome is 60% with a false positive rate of 5%. A combination of Nuchal translucency, Nasal bone visualization and biochemical tests (Combined test) increases the detection rate of Down syndrome to 85% at the same false positive rate.

Comments: First trimester screening for Prenatal disorders (Trisomy 21, 18 & 13) is essential to identify those women at sufficient risk for a congenital anomaly in the fetus to warrant further evaluation and followup. For Open neural tube defects, second trimester screening before 20 weeks is recommended. These are screening procedures which cannot discriminate all affected pregnancies from all unaffected pregnancies. Screening cutoffs are established by using MoM values that maximize the detection rate and minimize false positives.



 DR. LAVANYA LAGISETTY
 MD BIOCHEMISTRY

LABORATORY TEST REPORT

| | | | |
|--------------------|--------------------------------------|---------------|------------------------|
| Name | : Mrs. SUJATHA G | | |
| Sample ID | : A1840802 | | |
| Age/Gender | : 23 Years 1 Months 14 Days/Female | Reg. No | : 0312502140038 |
| Referred by | : Dr. M LAKSHMI | SPP Code | : SPL-CV-172 |
| Referring Customer | : V CARE MEDICAL DIAGNOSTICS | Collected On | : 14-Feb-2025 01:28 PM |
| Primary Sample | : Whole Blood | Received On | : 14-Feb-2025 04:07 PM |
| Sample Tested In | : Serum | Reported On | : 14-Feb-2025 06:56 PM |
| Client Address | : Kimtee colony ,Gokul Nagar,Tarnaka | Report Status | : Final Report |


IMMUNOLOGY & SEROLOGY

| Test Name | Results | Units | Biological Reference Interval |
|-----------|---------|-------|-------------------------------|
|-----------|---------|-------|-------------------------------|

 VDRL- Syphilis Antibodies
(Method: Slide Flocculation)

Non Reactive

Non Reactive

The serological diagnosis of syphilis is classified into two groups: Nontreponemal tests (RPR/VDRL) and Treponemal tests (TPHA/CLIA). Syphilis serology is a treponemal assay for the qualitative determination of antibodies to *T. pallidum* in human serum or plasma as an aid in the diagnosis of syphilis. Treponemal tests may remain reactive for life, even following adequate therapy thus a positive result suggests infection with *Treponema pallidum* but does not distinguish between treated and untreated infections. Therefore, the results of a nontreponemal assay, such as rapid plasma reagin, are needed to provide information on a patient's disease state and history of therapy. Nontreponemal tests lack sensitivity in late stage of infection and screening with these tests alone may yield false positive reactions in various acute and chronic conditions in the absence of syphilis (biological false positive reactions).

*** End Of Report ***



Page 2 of 5

DR. RUTURAJ MANIKLAL KOLHAPURE
 MD, MICROBIOLOGIST

LABORATORY TEST REPORT

| | | | |
|--------------------|--|---------------|------------------------|
| Name | : Mrs. SUJATHA G | | |
| Sample ID | : A1840802 | | |
| Age/Gender | : 23 Years 1 Months 14 Days/Female | Reg. No | : 0312502140038 |
| Referred by | : Dr. M LAKSHMI | SPP Code | : SPL-CV-172 |
| Referring Customer | : V CARE MEDICAL DIAGNOSTICS | Collected On | : 14-Feb-2025 01:28 PM |
| Primary Sample | : Whole Blood | Received On | : 14-Feb-2025 04:07 PM |
| Sample Tested In | : Serum | Reported On | : 14-Feb-2025 07:12 PM |
| Client Address | : Kimtee colony , Gokul Nagar, Tarnaka | Report Status | : Final Report |



IMMUNOLOGY & SEROLOGY

VIRAL SCREENING


| Test Name | Results | Units | Biological Reference Interval |
|--|---------|-------|------------------------------------|
| Hepatitis B Surface Antigen (HBsAg) (Method: ELISA) | 0.41 | S/Co | <1.00 :Negative >1.00 :Positive |

Interpretation:

- Negative result implies that antibodies to HBsAg have not been detected in the sample. This means the patient has either not been exposed to HBsAg infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non-Reactive result does not exclude the possibility of exposure or infection with HBsAg.
- Positive result implies that antibodies to HBsAg have been detected in the sample.

Hepatitis B Virus (HBV) is a member of the Hepadna virus family causing infections of the liver with extremely variable clinical features. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively sexually and from mother to baby. In most individuals HBV hepatitis is self limiting, but 1-2% normal adolescents and adults develop Chronic Hepatitis. Frequency of chronic HBV infection is 5-10% in immunocompromised patients and 80% in neonates. The initial serological marker of acute infection is HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symptoms. Persistence of HBsAg for more than six months indicates development of carrier state or Chronic liver disease.

HBV antigens and antibodies in the blood



Note:

1. All Reactive results are tested additionally by Specific antibody Neutralization assay . For further confirmation Molecular assays are recommended For diagnostic purposes, results should be used in conjunction with clinical history and other hepatitis markers for Acute or Chronic infection

*** End Of Report ***



[Signature]

LABORATORY TEST REPORT

| | | | |
|--------------------|--------------------------------------|---------------|------------------------|
| Name | : Mrs. SUJATHA G | | |
| Sample ID | : A1840802 | | |
| Age/Gender | : 23 Years 1 Months 14 Days/Female | Reg. No | : 0312502140038 |
| Referred by | : Dr. M LAKSHMI | SPP Code | : SPL-CV-172 |
| Referring Customer | : V CARE MEDICAL DIAGNOSTICS | Collected On | : 14-Feb-2025 01:28 PM |
| Primary Sample | : Whole Blood | Received On | : 14-Feb-2025 04:07 PM |
| Sample Tested In | : Serum | Reported On | : 14-Feb-2025 06:21 PM |
| Client Address | : Kimtee colony ,Gokul Nagar,Tarnaka | Report Status | : Final Report |



IMMUNOLOGY & SEROLOGY

VIRAL SCREENING


| Test Name | Results | Units | Biological Reference Interval |
|---|---------|-------|--|
| Hepatitis C Virus Antibody (Method: ELISA) | 0.22 | S/Co | < 1.00 : Negative > 1.00 : Positive |

Interpretation:

- Negative result implies that antibodies to HCV have not been detected in the sample. This means the patient has either not been exposed to HCV infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non-Reactive result does not exclude the possibility of exposure or infection with HCV.
- Positive result implies that antibodies to HCV have been detected in the sample.

Comments :-

Hepatitis C (HCV) is an RNA virus of Flavivirus group transmitted via blood transfusions, transplantation, injection drug users, accidental needle punctures in healthcare workers, dialysis patients and rarely from mother to infant. 10% of new cases show sexual transmission. As compared to HAV & HBV, chronic infection with HCV occurs in 85% of infected individuals. In high risk populations, the predictive value of Anti HCV for HCV infection is > 99% whereas in low risk populations it is only 25%.



Note:

- False positive results are seen in Autoimmune diseases, Rheumatoid factor, Hypergammaglobulinemia, Paraproteinemia, passive antibody transfer, Anti- idiotypes & Anti superoxide dismutase
- False negative results are seen in early Acute infection, Immunosuppression & Immuno-incompetence
- HCV RNA PCR recommended in all Reactive results to differentiate between past and present infection

*** End Of Report ***



[Signature]

LABORATORY TEST REPORT

| | | | |
|--------------------|--------------------------------------|---------------|------------------------|
| Name | : Mrs. SUJATHA G | | |
| Sample ID | : A1840802 | | |
| Age/Gender | : 23 Years 1 Months 14 Days/Female | Reg. No | : 0312502140038 |
| Referred by | : Dr. M LAKSHMI | SPP Code | : SPL-CV-172 |
| Referring Customer | : V CARE MEDICAL DIAGNOSTICS | Collected On | : 14-Feb-2025 01:28 PM |
| Primary Sample | : Whole Blood | Received On | : 14-Feb-2025 04:07 PM |
| Sample Tested In | : Serum | Reported On | : 14-Feb-2025 06:19 PM |
| Client Address | : Kimtee colony ,Gokul Nagar,Tarnaka | Report Status | : Final Report |



IMMUNOLOGY & SEROLOGY

VIRAL SCREENING

| Test Name | Results | Units | Biological Reference Interval |
|--|---------|-------|--|
| HIV (1& 2) Antibody (Method: ELISA) | 0.34 | S/Co | < 1.00 : Negative > 1.00 : Positive |

*** End Of Report ***



Page 5 of 5

DR. RUTURAJ MANIKLAL KOLHAPURE
MD, MICROBIOLOGIST

Prisca 5.1.0.17
Date of report: 14/02/25

N A

| Patient data | | | |
|--|----------------|---------------------------------|--|
| Name | Mrs. SUJATHA G | | Patient ID |
| Birth day | 01/01/02 | | Sample ID |
| Age at sample date | 23.1 | | Sample Date |
| Gestational age | 13 + 0 | | |
| Correction factors | | | |
| Fetuses | 1 | IVF | no |
| Weight | 50 | diabetes | no |
| Smoker | no | Origin | Asian |
| | | Previous trisomy 21 pregnancies | unknown |
| Biochemical data | | Ultrasound data | |
| Parameter | Value | Corr. MoM | Gestational age |
| PAPP-A | 11.21 mIU/mL | 1.90 | Method |
| fb-hCG | 35.74 ng/mL | 0.90 | Scan date |
| Risks at sampling date | | | Crown rump length in mm |
| Age risk | 1:1043 | | Nuchal translucency MoM |
| Biochemical T21 risk | <1:10000 | | Nasal bone |
| Combined trisomy 21 risk | <1:10000 | | Sonographer |
| Trisomy 13/18 + NT | <1:10000 | | Qualifications in measuring NT |
| | | | MD |
| Risk | | | Trisomy 21 |
| | | | <p>The calculated risk for Trisomy 21 (with nuchal translucency) is below the cut off, which indicates a low risk.</p> <p>After the result of the Trisomy 21 test (with NT) it is expected that among more than 10000 women with the same data, there is one woman with a trisomy 21 pregnancy.</p> <p>The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician. Please note that risk calculations are statistical approaches and have no diagnostic value!</p> <p>The patient combined risk presumes the NT measurement was done according to accepted guidelines (Prenat Diagn 18: 511-523 (1998)).</p> <p>The laboratory can not be hold responsible for their impact on the risk assessment ! Calculated risks have no diagnostic value!</p> |
| Trisomy 13/18 + NT | | | |
| <p>The calculated risk for trisomy 13/18 (with nuchal translucency) is < 1:10000, which represents a low risk.</p> | | | |

Sign of Physician

below cut off
 Below Cut Off, but above Age Risk
 above cut off